作者:Faridoon, None、Zheng, Jiyue、Zhang, Tao、Tong, Shuilong、Liu, Tao、Cui, Jiuen、Xu, Haojie、Hu, Di、Shen, Ying、Yin, Yajing、Zhao, Danhua、Tan, Chensheng、Dong, Xue、Chen, Jiali、Ji, Feihong、Tong, Chenhua、Li, Jie Jack、Li, Jiapeng、Zhang, Guiping
DOI:10.1021/acs.jmedchem.4c00552
日期:——
Synthetic lethality has recently emerged as a new approach for the treatment of mutated genes that were previously considered undruggable. Targeting methionine adenosyltransferase 2A (MAT2A) in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene leads to synthetic lethality and thus has attracted significant interest in the field of precise anticancer drug development. Herein
合成致死最近已成为治疗以前被认为无法成药的突变基因的新方法。通过删除甲硫腺苷磷酸化酶 (MTAP) 基因来靶向癌症中的甲硫氨酸腺苷转移酶 2A (MAT2A) 可导致合成致死性,因此引起了精准抗癌药物开发领域的极大兴趣。在此,我们报告了基于结构药物设计的一系列新型 MAT2A 抑制剂的发现,这些抑制剂具有吡唑并[3,4- c ]喹啉-4-酮骨架。进一步优化得到了化合物39 ,它具有高效抑制 MAT2A 的功效,并且对 MTAP 缺失的癌细胞系具有显着的选择性。化合物39具有良好的药代动力学特征、高血浆暴露量和口服生物利用度,并且在异种移植 MTAP 耗尽模型中表现出显着的功效。此外, 39在大鼠中表现出出色的大脑暴露, K puu为 0.64。